Mortality figures were calculated for a group of 717 Dutch haemophiliacs over the period 1973-86. Followup was on average 10-9 years; no patients were lost to followup. The data were compared to the general male population by actuarial methods and patient-year analysis. Forty-three patients died, while 20 deaths were expected in a hypothetical group of non-haemophiliacs of the same age distribution. Hence, overall mortality was 2·l times higher than in the general population. This leads to a calculated life expectancy of 66 years, äs compared to 74 years in the general male
population. Mortality did not differ much by severity of haemophilia. A possibly beneflcial effect of prophylaxis on longevity was observed. Haemorrhage occurred in half of all deaths and among these traumatic bleeding was the most prevalent. The number of deaths due to ischaemic heart disease was significantly lower (80% reduction) than expected and therefore the authors conclude that haemophilia offers protection against ischaemic heart disease. Cancer mortality was significantly higher (2-5 times) than expected.
Life expectancy in haemophilia was very low until the introduction of coagulation factor preparations made effective replacement therapy possible. Patients with severe haemophilia usually did not live beyond early adulthood, while even the life expectancy in mild haemophilia was reduced to about two-thirds of the normal life span (Sjölin, 1960; Ramgren, 1962; Ikkala et al, 1982; Larsson, 1985) . Recently, Larsson (1985) reported a much improved median life expectancy of 57 years in severe haemophilia over the period 1961-80. Although this flgure was still markedly below that of the general population, he also observed that the death rates for the younger patients in the last 10 years of his study were approaching those of the general Swedish population. Johnson et al (1985) found the age-adjusted mortality among United States haemophiliacs during 1978-82 to be 2-3 times äs high äs that of the general male population. Some deaths may have been missed, however, since this result was based on reported deaths and visits to haemophilia centres, rather than on a cohort study. Before 1960, virtually caused by haemorrhage (Nour-Eldin, 1961; Ramgren, 1962; Ikkala et al, 1982; Wolff et al, 1986) . The increased life expectancy and the concomitant increased average age of haemophiliacs now make it possible to study the occurrence of other causes of death in haemophilia and to compare these with the expected frequencies based on mortality figures from the general population. We set out to calculate mortality figures in haemophilia, based on haemophilia surveys that we started in 1973.
METHODS
The data were derived from haemophilia surveys carried out in 1973, 1978 and 1986 . These surveys consisted of mail questionnaires sent to the Dutch haemophiliacs. The patients were enrolled through the major Dutch haemophilia treatment centres and the Dutch Haemophilia Society. Severity of haemophilia was deflned by the percentage of factor VIII or factor IX clotting activity: severe haemophilia less than 1%, moderate haemophilia 1-5%, and mild haemophilia more than 5% clotting activity. If necessary, the Information from the patients' forms was supplemented with data from the haemophilia treatment centres.
Follow-up was performed for the respondents of the first two surveys and extended from either l January 1973 or l 71 June 1978 up to l January 1986, which were the closmg dates of the three surveys Information was obtamed about all 717 patients who responded to the previous surveys, either frora their response to the latest survey, or by inquines of the mumcipal registnes In this way none of the mdividuals was lost to follow-up We compared mortality m our patient group with the general population m two ways Both allowed the expression of mortality äs a ratio of observed over expected mortality First, the actuanal survival was calculated by life table methods, and compared with the survival of a hypothetical cohort of identical age distnbution from the general male population So, we mcorporated the national mortality flgures for all consecutive years of the follow-up penod (Netherlands Central Bureau of Statistics, 1973 -86, 1984 Secondly, we compared cause-speciflc mortality by the patient-year method This calculation was performed by multiplymg the number of patient-years of follow-up for each age category of the cohort with the correspondmg causespecific mortality rates in the general male population, and summmg over the age classes The observed/expected ratio arnved at m this way is the standardized mortality ratio (SMR) In the calculation of cause specific mortality the population flgures of 1979 were used For statistical analysis we used the Poisson distnbution to calculate confidence hmits and exact significance levels and chi-square tests
RESULTS
Mortality flgures were calculated for a cohort of 717 patients, consisting of the respondents of the 1973 and 1978 surveys A response rate of 84% to the flrst and 70% to the second survey resulted in 481 patients entering the study m 1973, whüe an additional 236 entered in 1978 An extensive and by all practical means exhaustive search led to a mailing to 1162 haemophihacs in our latest survey m 1986 This number, considermg a population of 14 5 million Dutch, gives a prevalence of eight per 100 000, so it can be inferred that the cohort of 717 patients formed about 65% of all Dutch haemophihacs, when we take the growth of the general population into account Nme hundred and thirty-flve patients responded in our 1986 survey (80%) Mean followup was 10 9 years None of the 717 patients was lost to follow-up The mean age at entrance m the study was 23 years Table I shows Forty-three patients died dunng the study mterval, while 20 4 deaths were expected when we applied age-speciflc population mortality rates Therefore, relative mortality, the ratio of observed over expected mortality, was 2 l, i e mortality was twice äs high in the haemophihacs äs in the general male population (Fig 1) Relative mortality was 2 9 in severe, and only l 6 m mild haemophilia When we excluded the small group of Inhibitor patients, however, relative mortality did not differ much by seventy of haemophilia The mean age of death was 49 years The median life expectancy was calculated also by life table method, by applymg the population mortality flgures multiphed by the relative mortality at each age mterval For this calculation to be vahd an equal distnbution of relative mortality over age has to be assumed The median life expectancy is the age at which half of a hypothetical cohort of newborns had died It was 74 years for the Dutch male population, and estimated at 66 years for a relative mortality of 2 l (Table II) Among the patients with severe haemophilia 24 (7%) had an mhibitor Six of these patients died, but only 14 of the 297 patients without an mhibitor died (χ 2 = 12 4, P<0 0004) | Inhibitor patients had a 5 3 times higher nsk of dymg than the patients without an mhibitor (95% confidence mterval l 9-11 5) This was not due to a difference m age on the contrary, the mhibitor patients were on average shghtly younger (half a year) at their entrance to the study than the other patients with severe haemophilia One hundred and twenty-nme (43%) of the 297 patients with severe haemophilia, mhibitor patients excluded, received prophylactic Substitution therapy durmg the whole or, more frequently, part of the study mterval Only three deaths occurred in the prophylaxis group, while 11 patients died among the 168 haemophihacs who did not receive prophylaxis Part of this difference was caused by a different age-distnbution patients receivmg prophylaxis were on average 5 years younger at their entrance in this study After age adjustment, however, mortality was still lower m the patients who received prophylactic treatment the relative mortality was l 9, äs compared to 2 5 among the patients who were not treated prophylactically This difference was 2 5 8 6 2 6 2 5 5 0 30 0 1 4-4 2 3 1-18 7 1 0-5 7 0 3-9 0 1 8 10 9 6 0-88 0 Ischaemic heart disease 5 0 0 2 0 0-1 l * The expected number of deaths was calculated by patient-year analysis, the observed/expected ratio is the standardized mortahty ratio (SMR) The 95% confidence interval apphes to this ratio not statistically sigmficant, but the power to detect such a difference was weak, due to the small number of deaths Causes of death could be obtamed m 40 out of 43 deceased patients (Table III) At least 20 deaths were caused by haemorrhage, although m several patients an underlymg lethal disorder existed Traumatic bleedmg was the most orevalent. One death was caused by an allergic reaction to cryoprecipitate with glotüs oedema, m three deaths the cause was renal disease, a frequent comphcation in haemophilia (Prentice et al, 1971; Lazerson, 1976) . No other therapyassociated deaths occurred: no cases of AIDS among haemophihacs were known in the Netherlands at the end of the follow-up penod and none of the reported death causes could be attnbuted to AIDS Specifically, there were no tumours of lymphatic tissue or opportumstic mfections Surpnsmgly, no deaths caused by liver disease were reported. All deaths in Inhibitor patients were caused by bleeding. Five of the 11 deaths in patients with severe haemophilia not treated prophylactically were associated with haemorrhage, but none of the three deaths in the patients receiving prophylaxis.
Patient-year analysis provided the age adjusted expected number of deaths for each cause (Table IV) . This showed a higher-than-expected mortality of several causes that are not (directly) associated with the bleeding tendency. For neoplasms the observed number of deaths was 2-5 times the expected number. More than half of this excess cancer mortality was caused by lung tumours. In sharp contrast to this, the number of deaths from ischaemic heart disease was lower than the calculated expected number: while flve were expected only one was observed, a signiflcant reduction (P-0-03, one-sided test). This low mortality due to ischaemic heart disease occurred in the face of a high prevalence of hypertension, at least äs judged by the use of antihypertensive medication. In our latest survey we found 26% of the severely affected patients aged 40-65 to use antihypertensive drugs, compared to 8% in moderate and mild haemophilia.
DISCUSSION
Our results indicate a mortality risk in haemophilia that is twice the risk that applies to the general male population. This implies an enormous advance compared to only a few decades ago, but still leads to a calculated loss of 8 years on median life expectancy. Most improvement has been made in severe haemophilia, and hence the death rates in severe, moderate and mild haemophilia were not very different. Inhibitor patients had a far less favourable prognosis. Analysis of the causes of death revealed a very low occurrence of deaths due to ischaemic heart disease, while an excess of neoplastic deaths, especially from lung cancer, was observed.
The patient group of this study was formed by the respondents of our mail surveys of 1973 and 1978. Because of the high overall response rate of 79% and the long period of follow-up we do not think that non-response introduced an important bias. It is likely, however, that selection occurred before the questionnaires were sent in the acquisition of addresses from the major haemophilia care centres and the Dutch Haemophilia Society. Patients with mild haemophilia probably are underrepresented, since their disease may remain undetected for many years if not for life and, moreover, because many of these patients are not registered in a major haemophilia centre.
We are confldent that the acquisition of addresses of the severely affected patients was fairly complete. The 321 patients with severe haemophilia were included by sending questionnaires to over 400 patients. If these were all patients with severe haemophilia living in 1979, the prevalence of severe haemophilia would be 3-1/100000, which is similar to (Rizza & Spooner, 1983) or higher than (Larsson et al, 1982) flgures from reports from countries with excellent registration Systems. For our 1986 survey we carried out a far more extensive search, also including many small hospitals. This study, in our judgement, includes practically all known Dutch haemophiliacs. Our efforts, however, did not lead to an increased number of addresses of patients with severe haemophilia, whereas 50% more patients with mild haemophilia were included. This implies that selection was limited to mild haemophilia.
Prophylactic Substitution therapy possibly reduces mortality in comparison to Όη-demand' treatment. Intensive therapy also carries the risk of transfusion-transmitted diseases. In our study deaths from AIDS or liver disease were absent. The prevalence of antibodies to the human immunodeficiency virus (HIV) among Dutch haemophiliacs is lower than in many other countries: 21% for severe haemophilia (Rosendaal et al, 1988) . This is most likely due to the predominant use of plasma products from local nonpaid donors and a large use of cryoprecipitate in The Netherlands. As Wolfs et al (1988) pointed out, about half of the seroconversions occurred after 1983, which serves äs a further explanation for the absence of AIDS cases up to l * January 1986. Aronson (1988) , reporting on almost 1000 deaths of U.S.A. haemophiliacs from 1968 to 1979, found 9% of deaths to be caused by liver disease. Among 107 deaths of haemophilia patients in Great Britain between 1976 and 1980, 2% died of liver disease, while about half of the patients were treated with commercially produced plasma products (Rizza & Spooner, 1983) . These data suggest that the origin of the clotting factor preparations plays a role in the prevalence of liver disease, äs has been reported by Spero et al (1979) . Aledort et al (1985) , however, found no association between the occurrence of severe liver disease and the product used.
We observed a large excess of cancer deaths, which was in part caused by neoplasms of the lung. Since the chance of surviving a carcinoma of the lung is generally low, this can only be fully explained by a raised incidence. A simple hypothesis is that haemophiliacs smoke more often than others, which might be related to their physical disability. The administration of blood transfusion during surgery has been reported to lead to less rejections of renal transplants ( Opelz et al, 1973) , and higher recurrence rates of malignan-* cies (Burrows & Tarttes, 1982) , possibly caused by immunosuppression. Immune alterations have also been demonstrated in poly-transfused haemophiliacs (Brettler et al, 1986; Madhok et al, 1986) . Although the role of the clotting system in metastasis is a matter of controversy (Bastida, 1985) , it may well be possible that the absence of fibrin formation around microscopic tumours enhances early metastasis in haemophilia patients which, combined with immune abnormalities, raises the cancer incidence.
The relative mortality due to ischaemic heart disease was significantly lower in haemophiliacs than in the general male population. This reduction is remarkable when viewed in the light of the raised mortality of many other causes. The high prevalence of hypertension among haemophiliacs makes this finding even more impressive. Autopsy series have shown that haemophilia does not prevent the development of atherosclerosis (Dalldorf et al, 1981; Small et al, 1983) . Consequently, we think that delayed fibrin formation may protect patients with haemophilia against coronary thrombosis and myocardial infarction (DeWood et al, 1980; Report of the Sixty-plus Reinfarction Study Research Group, 1980) . This protection is only partial, since myocardial infarction in haemophiliacs has been reported occasionally (Boivin, 1954; Borchgrevink, 1959) . Three earlier reports on deaths in haemophilia, together reporting on more than 200 deaths, also seem to show a deflcit of deaths by myocardial infarction (Johnson et al, 1985; Rizza & Spooner, 1983; Schiller et al, 1985) , although we were not able to calculate the combined observed-expected ratio from the published data. One report, covering 118 deaths over the period 1957-80 in Sweden, does not show a deficit (Larsson & Wiechel, 1983) . Aronson (1988) found an inversed ratio of the number of cancer deaths over the number of deaths from ischaemic heart disease, suggestive of a decreased mortality from heart disease or an increased cancer mortality, or both. Since the life expectancy of haemophiliacs is gradually becoming normal, more patients will live to experience diseases of the elderly like ischaemic heart disease and a deficit will be easier to observe.
When studying mortality over a 13-year interval, recent changes are not reflected fully in the data. In the last few years, inhibitor patients have received treatment with low dose Substitution therapy which leads to the disappearance of many inhibitors (Van Leeuwen et al, 1986) . Therefore, it is likely that the prognosis for these patients is far better now than during the years of our study. In the immediate future AIDS, äs well äs liver disease, will have an effect on mortality, the impact of which may differ from country to country. However devastating, these effects will be temporary. For the future we expect the disappearance of possible carry-over effects from the past, when more and more patients will have received adequate therapy from childhood.
